Loading…
Spyre Therapeutics, Inc. is projected to rise to $96.50 by 2027, a +33% move from its current price of $72.51. SYRE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $70.28 | $72.54 | $74.88 | +0.05% |
| May 30 | $69.39 | $72.58 | $75.91 | +0.09% |
| May 31 | $68.73 | $72.61 | $76.72 | +0.14% |
| Jun 1 | $68.18 | $72.65 | $77.41 | +0.19% |
| Jun 2 | $67.70 | $72.68 | $78.03 | +0.24% |
| Jun 3 | $67.28 | $72.72 | $78.60 | +0.29% |
| Jun 4 | $66.89 | $72.75 | $79.13 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $66.89 | $72.75 | $79.13 | +0.33% |
| Week 2 | $64.82 | $72.99 | $82.20 | +0.67% |
| Week 3 | $63.32 | $73.24 | $84.70 | +1.00% |
| Week 4 | $62.12 | $73.48 | $86.92 | +1.34% |
| Week 5 | $61.10 | $73.72 | $88.96 | +1.67% |
| Week 6 | $60.21 | $73.97 | $90.87 | +2.01% |
| Week 7 | $59.43 | $74.22 | $92.68 | +2.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spyre Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. It develops SPY001, a humanized monoclonal immunoglobulin G1 antibody in phase-2 designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 — anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc.
in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
SYRE is Spyre Therapeutics, Inc., trading at $74.05 per share with a market capitalization of $6.43B and a rank of 1165. The price outlook is anchored in a multi-year forecast that spans 2026 to 2050, with 2026 average price of $74.05 and 2050 average price of $1,158.91. The forecast shows a sequence of rising averages across years, including 2027 avg $99.22, 2028 avg $144.61, 2029 avg $169.89, 2030 avg $187.91, 2040 avg $538.70, and 2050 avg $1,158.91, with corresponding ROIs of 34%, 95.3%, 129.4%, 153.8%, 627.5%, and 1465% respectively.
These figures outline a structurally bullish long-run outlook, tempered by the inherent uncertainty of clinical and market factors.
A major floor 55.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 5.4% above — a clean break opens room to run.
A major ceiling 12.6% above — clearing it would confirm fresh momentum.
Key SYRE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SYRE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $73.29 | Sell | $72.96 | Sell |
| MA 10 | $73.00 | Sell | $72.88 | Sell |
| MA 20 | $72.93 | Sell | $71.67 | Buy |
| MA 50 | $62.76 | Buy | $63.95 | Buy |
| MA 100 | $49.46 | Buy | $53.59 | Buy |
| MA 200 | $36.03 | Buy | $42.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.76 | Neutral |
| Stoch RSI (14) | 36.79 | Neutral |
| CCI (20) | -13.35 | Neutral |
| Williams %R (14) | -39.96 | Info |
| MACD (12,26,9) | -0.87 | Sell |
| ROC (12) | -3.38 | Sell |
| Bollinger %B (20,2) | 0.46 | Neutral |
| Stochastic %K (14) | 60.04 | Neutral |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 2.77 | Buy |
| Ultimate (7,14,28) | 46.21 | Neutral |
| Momentum (10) | -2.53 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 74.16 | Sell |
| ADX (14) | 26.11 | Buy |
| ATR (14) | 1.98 | Info |
The 30-day technical picture is bullish. The RSI (14-day) sits at 60, with the 50-day simple moving average at $61.52 and the 200-day simple moving average at $35.45. Price currently sits above both moving averages, indicating positive near-term momentum.
The stock trades within a 30-day range of $59.36 to $92.38, with nearby support at $63.27 and resistance at $76.43.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.96 | $72.51 | $109.57 | 0% | Neutral | |
| $75.33 | $96.50 | $131.67 | +33% | Bullish | |
| $105.81 | $139.97 | $198.87 | +93% | Bullish | |
| $122.48 | $166.46 | $244.18 | +130% | Bullish | |
| $132.68 | $184.72 | $278.35 | +155% | Bullish | |
| $148.01 | $210.67 | $325.00 | +191% | Bullish | |
| $143.11 | $207.96 | $327.65 | +187% | Bullish | |
| $166.12 | $246.14 | $395.28 | +239% | Bullish | |
| $213.86 | $322.82 | $527.61 | +345% | Bullish | |
| $230.89 | $354.81 | $589.40 | +389% | Bullish | |
| $321.20 | $535.72 | $952.59 | +639% | Bullish | |
| $612.01 | $1,179.30 | $2,314.24 | +15.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $29.96 | $72.51 | $84.92 | +0.00% |
| June 2026 | $61.13 | $72.05 | $87.12 | -0.64% |
| July 2026 | $63.62 | $75.72 | $92.99 | +5.09% |
| August 2026 | $64.31 | $77.13 | $95.86 | +1.87% |
| September 2026 | $64.01 | $77.27 | $96.96 | +0.17% |
| October 2026 | $67.12 | $81.49 | $103.16 | +5.46% |
| November 2026 | $70.27 | $85.76 | $109.41 | +5.25% |
| December 2026 | $69.53 | $85.27 | $109.57 | -0.57% |
Click any year to see its month-by-month SYRE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SYRE price prediction for 2026 points to an average of $72.51 (low $29.96, high $109.57) — a potential gain of 0% on today's $72.51. Price action looks broadly range-bound.
In 2027, SYRE is projected to trade between $75.33 and $131.67, averaging $96.50 — a potential gain of +33% from today's $72.51. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Spyre Therapeutics, Inc.'s 2028 outlook centres on $139.97, within a $105.81 to $198.87 range. That is up +45% on the projected 2027 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2029, SYRE could reach as high as $244.18, with a base case around $166.46 and support toward $122.48 — roughly +130% from $72.51. Buyers look set to stay in control over this stretch.
Expect SYRE to range from $132.68 to $278.35 through 2030. The $184.72 average target implies a +155% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The SYRE price prediction for 2031 points to an average of $210.67 (low $148.01, high $325.00) — a potential gain of +191% on today's $72.51. Buyers look set to stay in control over this stretch.
In 2032, SYRE is projected to trade between $143.11 and $327.65, averaging $207.96 — a potential gain of +187% from today's $72.51. That is -1% versus the projected 2031 average. Momentum favours further upside here.
Spyre Therapeutics, Inc.'s 2033 outlook centres on $246.14, within a $166.12 to $395.28 range. That is up +18% on the projected 2032 average. That marks a +239% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SYRE could reach as high as $527.61, with a base case around $322.82 and support toward $213.86 — roughly +345% from $72.51. Momentum favours further upside here.
Expect SYRE to range from $230.89 to $589.40 through 2035. The $354.81 average target implies a +389% move from current prices. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The SYRE price prediction for 2040 points to an average of $535.72 (low $321.20, high $952.59) — a potential gain of +639% on today's $72.51. Momentum favours further upside here.
In 2050, SYRE is projected to trade between $612.01 and $2,314.24, averaging $1,179.30 — a potential gain of +15.3x from today's $72.51. That is up +120% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SYRE today (≈ 13.791201 SYRE) could be worth
$16,264.02
+$15,264.02 (+1526%) by 2050 · US Dollar
Based on the average projected SYRE price of $1,179.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SYREwould be worth at today's price.
$1,000 invested in SYRE on May 27, 2025 (≈ 66.711142 SYRE) would be worth
$4,837.22
+$3,837.22 (+383.7%) today · 4.84× · US Dollar
Based on a SYRE entry price of $14.99 vs. today's $72.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $71.92 | $1,008.2 | +0.8% |
| 1 month ago | $71.9 | $1,008.48 | +0.8% |
| 3 months ago | $43.15 | $1,680.42 | +68.0% |
| 6 months ago | $30 | $2,417 | +141.7% |
| 1 year ago | $14.99 | $4,837.22 | +383.7% |
| All time (5.0y) ago | $173.25 | $418.53 | -58.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SYRE forecast.
Our base-case forecast reaches $150.00 around 2029.
Implied market cap at $150.00: $13.03B
The multi-year forecast shows a persistent bullish trajectory, with the average price rising from $74.05 in 2026 to $1,158.91 in 2050 and notable increases along the way. By 2030, the average is $187.91 with a ROI of 153.8%. The forecast then projects continued growth, with the 2040 average at $538.70 and a ROI of 627.5%, and the 2050 average reaching $1,158.91 with a ROI of 1465%.
Earlier years also show rising averages: 2027 avg $99.22 (ROI 34%), 2028 avg $144.61 (ROI 95.3%), 2029 avg $169.89 (ROI 129.4%), 2031 avg $212.67 (ROI 187.2%), 2032 avg $207.16 (ROI 179.8%), 2033 avg $249.30 (ROI 236.7%), and beyond. These estimates illustrate a strong long-run growth path but are not guarantees and depend on clinical, regulatory, and market dynamics.
Tap a question to reveal the answer.
The forecast shows 2030 avg price of $187.91 with a min of $133.30 and a max of $286.95, and a ROI of 153.8%; sentiment is BULLISH.
The outlook becomes bullish from 2027 onward, with 2027 avg $99.22 and ROI 34%, rising to 2030 avg $187.91 and ROI 153.8%, and reaching 2050 avg $1,158.91 with ROI 1465%, though 2026 is neutral with ROI 0%.
Yes. The 2027 max is $136.61 and the 2028 min is $108.33, while the 2028 average is $144.61, indicating the price could exceed $100 in the near term within the forecast window.
Sentiment is BULLISH. RSI (14) is 60, SMA50 is $61.52, SMA200 is $35.45. Support is at $63.27 and resistance at $76.43, with a 30-day range of $59.36 to $92.38.
Current price is $74.05 and market capitalization is $6.43B; the rank is 1165.
Spyre Therapeutics, Inc. Community Discussion
0Share your Spyre Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.